Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
121
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,176.20 | 29.20 | -0.32% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,694.37 | 427.03 | -0.85% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 27,032.54 | 233.84 | -0.86% |
| NASDAQ | 22,726.81 | 339.66 | -1.47% |
| Nikkei 225 | 57,256.74 | 383.10 | -0.66% |
| NZX 50 Index | 13,357.95 | 149.33 | -1.11% |
| S&P 500 | 6,872.16 | 69.31 | -1.00% |
| S&P/ASX 200 | 8,951.40 | 21.50 | -0.24% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |